scholarly journals A Safe Start Laparoscopic-assisted Pancreaticoduodenectomy in Songklanagarind Hospital, Thailand: Case Report

2021 ◽  
Author(s):  
Tortrakoon Thongkan ◽  
Nan-ak Wiboonkhwan ◽  
Thakerng Pitakteerabundit ◽  
Piyanun Wangkulangkul
Keyword(s):  
Initial Phase ◽  
High Volume ◽  
Laparoscopic Pancreaticoduodenectomy ◽  
Distal Cholangiocarcinoma ◽  
Postoperative Course ◽  
Oncological Outcomes ◽  
Complex Procedure ◽  
High Volume Center ◽  
Laparoscopic Assisted

Total laparoscopic pancreaticoduodenectomy (PD) is a highly complex procedure. Evidence suggests laparoscopic-assisted PD (LAPD) might be an important link in the process of transition from open PD to total laparoscopic PD. We present the first successful LAPD in a female patient with distal cholangiocarcinoma at Songklanagarind Hospital, Thailand in July 2018. The postoperative course was satisfactory without the clinical relevance of complications. No evidence of recurrence was found after 35 months of follow-up. The results ensured the feasibility and safety of LAPD in the initial phase; regarding both complications and oncological outcomes in a high-volume center for open PD.

Survival analyses of adjuvant or neoadjuvant combination of a taxane plus cisplatin and 5-fluorouracil (T-PF) in patients with bulky nodal metastases from squamous cell carcinoma of the penis (PSCC): Results of a single high-volume center.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 377-377 ◽  
Author(s):  
Patrizia Giannatempo ◽  
Anna Paganoni ◽  
Laura Sangalli ◽  
Maurizio Colecchia ◽  
Luigi Piva ◽  
...  
Keyword(s):  
Progression Free Survival ◽  
High Volume ◽  
Wilcoxon Test ◽  
Nodal Metastases ◽  
Primary Endpoints ◽  
Negative Prognostic Factor ◽  
High Volume Center ◽  
Secondary Endpoints ◽  
P53 Status

377 Background: Bulky nodal metastases (N2-N3) of PSCC represent a negative prognostic factor, yet efficacy of multimodal treatment is not defined. For these patients (pts) we explore T-PF combination in adjuvant and neo-adjuvant setting. Methods: Paclitaxel (120 mg/m2, d1) or docetaxel (75 mg/m2 d1) plus cisplatin (75-100 mg/m2 d1) and 5-fluorouracil (5FU, 750-1000 mg/m2 96h d1) were scheduled prior to or following radical inguino-pelvic dissections in N2-3 M0 pts, according to protocol indications. Primary endpoints were overall (OS) and progression-free survival (PFS); safety and response-rate represented secondary endpoints. Association of survival with treatment setting and pre-specified covariates was explored. Results: From 6/2004 to 10/2012, 47 consecutive pts received neoadjuvant (N=28) or adjuvant (N=19) T-PF. 18 (38.3%) were disease-free after a median follow-up (FU) of 22 mos (IQR 17-42). Durable remissions were more frequently observed in adjuvant (52.6%; median FU: 42 mos) than in neoadjuvant group (28.6%; median FU: 17 mos). Distribution of OS and PFS were statistically in favour of adjuvant T-PF (p=0.01 at Wilcoxon test; p=0.008 at t test). However, Kaplan-Meyer curves did not show significant differences. A model including therapy setting, N category, laterality, pelvic extent and p53 status showed that only adjuvant administration was associated with improved OS (p=0.008), while adjuvant therapy (p=0.002), pelvic extent (p=0.029) and laterality (p=0.086) were associated with PFS. In neoadjuvant group we recorded 43% responses (complete [CR] and partial) and 4 (14%) pathologic CR. Surgery was possible in 18 (64.3%) pts, independently of response. Neither OS nor PFS were associated with response. Tolerability was mild to moderate. Conclusions: Adjuvant chemotherapy was the most important favourable predictor of OS and PFS. Adjuvant T-PF results are among the best available ones. Neoadjuvant T-PF compares with other recent schedules in terms of activity and efficacy. Surgery remains the mainstay treatment for resectable nodal metastases from PSCC.

scholarly journals Feasibility of robot-assisted radical prostatectomy in men at senior age ≥75 years: perioperative, functional, and oncological outcomes of a high-volume center

2021 ◽  
Vol 25 (1) ◽  
pp. 8-16
Author(s):  
Sami-Ramzi Leyh-Bannurah ◽  
Christian Wagner ◽  
Andreas Schuette ◽  
Nikolaos Liakos ◽  
Theodoros Karagiotis ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
High Volume ◽  
Robot Assisted ◽  
Oncological Outcomes ◽  
High Volume Center

Sequential salvage chemotherapy for CDDP-refractory advanced testicular cancer: Japanese high-volume center experience.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15526-e15526
Author(s):  
Terukazu Nakamura ◽  
Yasunori Kimura ◽  
Takashi Ueda ◽  
Yoshio Naya ◽  
Fumiya Hongo ◽  
...  
Keyword(s):  
Overall Survival ◽  
Testicular Cancer ◽  
Clinical Outcomes ◽  
High Volume ◽  
Salvage Chemotherapy ◽  
Line Therapy ◽  
Significant Difference ◽  
High Volume Center ◽  
Advanced Testicular Cancer

e15526 Background: Chemotherapy- refractory or resistant GCTs, so called ‘difficult-to-treat’ GCTs would remain continuously disease-free with salvage chemotherapy or surgery. The optimal salvage chemotherapy remains unclear. The aim of this study was to assess the efficacy of ‘sequential’ chemotherapy for advanced testicular cancer. Methods: Salvage chemotherapy was required in 129 patients out of 233 advanced GCTs treated at Kyoto Prefectural University of Medicine from June, 1998 to December, 2011. Clinical outcomes were retrospectively assessed. Results: Median age was 31 year-old (range:17-65y.o.). Non-seminoma was in 111 cases (86.0%). IGCCC showed good in 37 cases (28.9%), intermediate 33 (25.6%), poor 47 (36.4%), and unknown 12 (9.1%). As the 2nd line therapy, VIP/VeIP and TIP/N therapy were done in 43 (33.3%) and 49 cases (38.0%), respectively. With regard to the patients requiring 3rd line or more chemotherapy, 95, 67, 40, 26 cases had 3rd, 4th, 5th and 6th line or more chemotherapy, respectively. TIN therapy was performed in 48 patients as 3rd line and in 24 patients as 4th line. Irinotecan-containing chemotherapy was done in 24 and 36 cased as 2nd +3rd line therapy and 4th line or more, respectively. Gemcitabine-containing therapy was done in 33 cases with 3rdline or more chemotherapy. Overall survival rate at median follow-up period was 71.0%at median follow-up of 48m. Overall survival stratified by IGCCC was shown in the figure. There was no significant difference between any two groups. Clinical outcomes showed no evidence of disease (NED) was obtained in 86.1% with second line therapy. Noteworthy mentioned, about 40% patients had NED even in the 4thline or more chemotherapy group. Conclusions: Relatively good prognosis was obtained in the patients with salvage chemotherapy at Japanese high volume center. Sequential continuous chemotherapy would be very important to manage ‘difficult-to-treat’ advanced germ cell tumors.

Determining optimal follow up for patients with anal cancer following chemoradiation.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 689-689
Author(s):  
Marissa Frazer ◽  
George Q Yang ◽  
Seth Felder ◽  
Julian Sanchez ◽  
Sophie Dessureault ◽  
...  
Keyword(s):  
Health Care ◽  
Anal Carcinoma ◽  
High Volume ◽  
Disease Recurrence ◽  
First Year ◽  
High Volume Center ◽  
High Control ◽  
Cancer Network

689 Background: U.S. health care is increasingly defined by over expenditure and inefficiency. Optimizing patient follow-up is critical especially in cancers treated with high control rates. The objective of this study was to assess time to disease recurrence or toxicity in a cohort of patients with anal carcinoma in order to optimize patient care. Methods: 140 patients diagnosed with biopsy-proven, non-metastatic anal carcinoma, treated with chemoradiation utilizing IMRT, were identified from an institutional database at our high volume center. After IRB approval, a retrospective study was conducted that evaluated local recurrence (LR), distant metastasis (DM), overall survival (OS), and late ≥ grade three toxicity (LG3T) based on National Cancer Institute Common Terminology for Adverse Events version 4. Patients were followed post-treatment every three months for two years, every six months in years 3-5 then yearly thereafter with imaging per National Comprehensive Cancer Network recommendations. Results: Median age and follow up is 58 years and 27 months, respectively. Patients were staged based on AJCC 8th edition and 24 patients were stage I (17%), 55 stage II (39%) and 61 stage III (44%). The median radiation dose was 54 Gy (range: 40-62.5), and 11% of patients required a radiation break. The two year LC, DMFS, and OS were 93%, 94% and 89% and 5-year LC, DMFS, OS were 92%, 87% and 85% respectively. In total, there were 29 disease or treatment related events: LR occurred in nine patients, DM in 11 patients, and LG3T in nine patients. Overall, 62% of events occurred within year one and 77 % within two years. Stratified by event type, at two years 79% of LR, 64% of DM and 89% LG3T were identified. At the remaining follow-up points after 2 years there was an event incidence rate of 1.4%. Conclusions: The majority of recurrences/toxicities in patients diagnosed with non-metastatic anal carcinoma after chemoradiation occur within the first year, with 77% of any event occurring before year two. The data from individual time points suggest a reduction in follow-up during years 3-5 may provide adequate surveillance. Considering revisions of the current follow-up recommendations could maximize health care resources while also improving patient quality of life.

Sign in / Sign up

Export Citation Format

Share Document